AMYLYX PHARMACEUTICALS INC (AMLX) Stock Analyst Earnings Estimates
NASDAQ:AMLX - Nasdaq - US03237H1014 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 22.23M 7,700.00% | 380.786M 1,612.94% | 87.371M -77.06% | -100.00% | 93.983K | 24.758M 26,243.12% | 90.714M 266.40% | 213.65M 135.52% | 363.41M 70.10% | 513.16M 41.21% | 631.38M 23.04% | |
| EBITDA YoY % growth | -200.854M -143.06% | 39.89M 119.86% | -162.273M -506.80% | -132.457M 18.37% | -235.253M -77.61% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -201.341M -143.49% | 38.802M 119.27% | -163.177M -520.54% | -164.294M -0.68% | -179.551M -9.29% | -190.748M -6.24% | -116.752M 38.79% | 7.371M 106.31% | 145.39M 1,872.46% | 330.99M 127.66% | 424.5M 28.25% | |
| Operating Margin | -905.72% | 10.19% | -186.76% | N/A | -191,046.78% | -770.45% | -128.70% | 3.45% | 40.01% | 64.50% | 67.23% | |
| EPS YoY % growth | -3.43 -84.77% | 0.70 120.41% | -2.47 -452.86% | -1.87 24.28% | -1.69 9.61% | -1.60 5.36% | -0.98 38.48% | -0.12 88.08% | 1.05 998.52% | 1.73 64.20% | 2.30 32.61% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.45 37.80% | -0.46 57.09% | -0.49 11.76% | -0.42 0.43% |
| Revenue Q2Q % growth | 100.00% | -100.00% | 100.00% | N/A |
| EBITDA Q2Q % growth | -42.879M 18.96% | -39.812M -2.84% | -42.781M -7.62% | N/A |
| EBIT Q2Q % growth | -41.669M 22.02% | -41.952M -6.32% | -44.826M -10.26% | -47.399M -25.39% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.42 -250.00% | -0.48 | 0.06 | 13.31% |
| Q4 2024 Q2Q % growth | -0.55 -885.71% | -0.53 | -0.02 | -3.70% |
| Q3 2024 Q2Q % growth | -1.07 -456.67% | -0.72 | -0.35 | -47.75% |
| Q2 2024 Q2Q % growth | -0.73 -335.48% | -0.74 | 0.01 | 1.96% |
| Q1 2024 Q2Q % growth | -0.12 -700.00% | -0.01 | -0.11 | -1,860.78% |
| Q4 2023 Q2Q % growth | 0.07 110.77% | 0.23 | -0.16 | -69.94% |
| Q3 2023 Q2Q % growth | 0.30 132.61% | 0.44 | -0.14 | -32.39% |
| Q2 2023 Q2Q % growth | 0.31 133.33% | 0.10 | 0.21 | 203.92% |
| Q1 2023 Q2Q % growth | 0.02 102.15% | -0.25 | 0.27 | 108.15% |
| Q4 2022 Q2Q % growth | -0.65 84.34% | -0.84 | 0.19 | 22.25% |
| Q3 2022 Q2Q % growth | -0.92 | -0.99 | 0.07 | 7.16% |
| Q2 2022 Q2Q % growth | -0.93 | -0.89 | -0.04 | -4.50% |
| Q1 2022 Q2Q % growth | -0.93 | -0.70 | -0.23 | -32.78% |
| Q4 2021 Q2Q % growth | -4.15 | -0.65 | -3.50 | -535.72% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -100.00% | % | ||
| Q4 2024 Q2Q % growth | -665K -100.61% | -665K | % | |
| Q3 2024 Q2Q % growth | 416K -99.59% | 416K | % | |
| Q2 2024 Q2Q % growth | -1.023M -101.04% | 10.876M | -11.899M | -109.41% |
| Q1 2024 Q2Q % growth | 88.643M 24.10% | 100.31M | -11.667M | -11.63% |
| Q4 2023 Q2Q % growth | 108.449M 395.54% | 109.1M | -651K | -0.60% |
| Q3 2023 Q2Q % growth | 102.693M 29,666.09% | 115.93M | -13.237M | -11.42% |
| Q2 2023 Q2Q % growth | 98.216M | 93.98M | 4.236M | 4.51% |
| Q1 2023 Q2Q % growth | 71.428M | 60.167M | 11.261M | 18.72% |
| Q4 2022 Q2Q % growth | 21.885M | 4.82M | 17.065M | 354.05% |
| Q3 2022 Q2Q % growth | 345K 21.05% | 84.997K | 260.003K | 305.90% |
| Q2 2022 Q2Q % growth | 84.997K | -84.997K | -100.00% | |
| Q1 2022 Q2Q % growth | 84.997K | -84.997K | -100.00% | |
| Q4 2021 Q2Q % growth | -100.00% | 729.3K | -729.3K | -100.00% |
| Q3 2021 Q2Q % growth | 285K -5.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 2% | 11.56% | -2.44% | 2.57% |
| Revenue | N/A | N/A | N/A | N/A |